Stock REMUS REMUS PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Remus Pharmaceuticals Limited

Equities

REMUS

INE0O5T01011

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 09:46:11 31/05/2024 BST 		5-day change 1st Jan Change
7,293 INR +1.28% Intraday chart for Remus Pharmaceuticals Limited -4.24% -4.71%
12:00am 790,000 Equity Shares of Remus Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI
05-16 Remus Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Business Summary

Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredient (API). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, tablet. The therapeutic areas it works include oncology, cardiovascular, anti-diabetic, immune suppressants, anti-biotic, antibacterial, dermatology, central nervous system, and others. Its oncology products include Sorafenib Tablets, Enzalutamide Capsules, Lenalidomide Capsule, and others. Its cardiovascular products include Rivaroxaban Tablets, Ticagrelor Tablets, and others.

Number of employees: 38

Sales per Business

INR in Million2021Weight2022Weight Delta
Finished Formulations
82.3 %
119 64.8 % 203 82.3 % +70.43%
Active Pharmaceutical Ingredients
15.1 %
65 35.2 % 37 15.1 % -42.31%
Services
2.6 %
- - 6 2.6 % -

Sales per region

INR in Million2021Weight2022Weight Delta
Bolivia
38.3 %
53 28.8 % 95 38.3 % +78.51%
Dominican Republic
18.6 %
36 19.4 % 46 18.6 % +28.62%
Albania
13.5 %
40 21.4 % 33 13.5 % -15.48%
India
6.3 %
31 16.7 % 16 6.3 % -49.46%
Venezuela
5.3 %
4 2.0 % 13 5.3 % +251.85%
Costa Rica
2.6 %
2 1.0 % 6 2.6 % +262.40%
United States
2.5 %
-- 6 2.5 % -
Saudi Arabia
2.3 %
-- 6 2.3 % -
Guatemala
1.7 %
10 5.4 % 4 1.7 % -57.00%
Kuwait
1.7 %
-- 4 1.7 % -
Namibia
1.5 %
-- 4 1.5 % -
Ecuador
1.5 %
-- 4 1.5 % -
Honduras
1.0 %
1 0.3 % 3 1.0 % +333.39%
Panama
0.9 %
-- 2 0.9 % -
Chile
0.9 %
3 1.6 % 2 0.9 % -26.30%
Uzbekistan
0.8 %
-- 2 0.8 % -
Jamaica
0.4 %
0 0.2 % 1 0.4 % +175.77%
Bhutan
0.3 %
-- 1 0.3 % -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,085,000 388,000 ( 35.76 %) 0 35.76 %

Shareholders

NameEquities%Valuation
Arpit Deepakkumar Shah
16.97 %
250,000 16.97 % 3 ₹
Swapnil Jatinbhai Shah
16.97 %
250,000 16.97 % 3 ₹
Roma Vinodbhai Shah
16.97 %
250,000 16.97 % 3 ₹
Anar Swapnil Shah
16.97 %
250,000 16.97 % 3 ₹
Hemant Ishwarlal Modi
0.3394 %
5,000 0.3394 % 0 ₹

Company contact information

Remus Pharmaceuticals Ltd.

1101 to 1103, South Tower, One42 Near Ashok Vatika, Bopal-Ambli Road

380058, Ahmedabad

+91 79 2999 9857

http://remuspharma.com
address Remus Pharmaceuticals Limited(REMUS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
REMUS PHARMACEUTICALS LIMITED Stock Remus Pharmaceuticals Limited
-4.71% 127M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.82% 734B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.94% 591B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.31% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.23% 315B
ABBVIE INC. Stock AbbVie Inc.
+0.86% 276B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.92% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-6.26% 204B
NOVARTIS AG Stock Novartis AG
+8.42% 206B
AMGEN INC. Stock Amgen Inc.
+4.51% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. REMUS Stock
  4. Company Remus Pharmaceuticals Limited